Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 36-44

  Serpa Neto, A ^a   Tobias Machado, M ^a,b   Esteves, M A P ^a,b   Senra, M D ^a,b   Wroclawski, M L ^a,b   Fonseca, F L A ^a,b   Dos Reis, R B ^c   Pompeo, A C L ^a   Giglio, A D ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

bisphosphonate; bone metabolism; fractures

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; BONE DENSITY; BONE METASTASIS; CANCER HORMONE THERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; META ANALYSIS; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

AGED; ANDROGENS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857042883     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.4     Document Type: Review

References (38)

1. Frydenberg M, Stricker PD, Kaye KW. Prostate cancer diagnosis and treatment. Lancet 1997; 349: 1681-1687.
2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-583. (Pubitemid 30323983)
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-2994. (Pubitemid 30413181)
4. Eaton CL, Colby L, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates treatment. Cancer Treat Rev 2003; 29: 189-198. (Pubitemid 36763943)
5. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45: 26-34. (Pubitemid 37548989)
6. Brufsky AM. Cancer treatment-induced bone loss: patophysiology and clinical perspectives. Oncol 2008; 13: 187-195. (Pubitemid 351342583)
7. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen- deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-899. (Pubitemid 38222847)
8. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis WHO Technical Report Series 843 World Health Organization: Geneva.
9. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-1007.
10. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006; 4: 257-262. (Pubitemid 43779882)
11. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003; 15: 458-463. (Pubitemid 36774259)
12. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-1450. (Pubitemid 32947828)
13. Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009; 182: 2257-2264.
14. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 17: 1300-1311. (Pubitemid 37160863)
15. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424. (Pubitemid 351650576)
16. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426-4434.
17. Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005; 47: 575-580. (Pubitemid 40521898)
18. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042. (Pubitemid 46596753)
19. Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. Int J Urol 2007; 14: 317-320. (Pubitemid 46669053)
20. Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007; 100: 70-75. (Pubitemid 46878544)
21. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176: 972-978. (Pubitemid 44142571)
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. (Pubitemid 38807610)
24. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebocontrolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284. (Pubitemid 46621802)
25. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012. (Pubitemid 36576705)
26. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
27. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. JADA 2006; 137: 1115-1119. (Pubitemid 44367957)
28. Cartos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes. JADA 2008; 139: 23-30.
29. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Systematic Review 2006; 4, Article number CD006250.
30. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol 2006; 13: 3180-3188.
31. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26: 5465-5476.
32. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177: 17-24. (Pubitemid 44879461)
33. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24-34.
34. Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis 2008; 11: 13-19. (Pubitemid 351250325)
35. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-3846. (Pubitemid 39071482)
36. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179: 152-155. (Pubitemid 350216737)
37. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F et al. Denosumab in men receiving androgendeprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
38. Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 2670-2675.